

MPZL2 Antibody (Center) Blocking Peptide
Synthetic peptide
Catalog # BP17697c**Specification**

MPZL2 Antibody (Center) Blocking Peptide - Product Information

Primary Accession [O60487](#)

MPZL2 Antibody (Center) Blocking Peptide - Additional Information

Gene ID 10205

Other Names

Myelin protein zero-like protein 2, Epithelial V-like antigen 1, MPZL2, EVA, EVA1

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

MPZL2 Antibody (Center) Blocking Peptide - Protein Information

Name MPZL2

Synonyms EVA {ECO:0000303|PubMed:9585423}, EVA1

Function

Mediates homophilic cell-cell adhesion.

Cellular Location

Membrane; Single-pass type I membrane protein

Tissue Location

Widely expressed. In fetal tissues, highest expression in the inner ear. In adult tissues, highest levels in thymus and lung.

MPZL2 Antibody (Center) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

MPZL2 Antibody (Center) Blocking Peptide - Images**MPZL2 Antibody (Center) Blocking Peptide - Background**

Thymus development depends on a complex series of interactions between thymocytes and the stromal component of the organ. Epithelial V-like antigen (EVA) is expressed in thymic epithelium and strongly downregulated by thymocyte developmental progression. This gene is expressed in the thymus and in several epithelial structures early in embryogenesis. It is highly homologous to the myelin protein zero and, in thymus-derived epithelial cell lines, is poorly soluble in nonionic detergents, strongly suggesting an association to the cytoskeleton. Its capacity to mediate cell adhesion through a homophilic interaction and its selective regulation by T cell maturation might imply the participation of EVA in the earliest phases of thymic organogenesis. The protein bears a characteristic V-type domain and two potential N-glycosylation sites in the extracellular domain; a putative serine phosphorylation site for casein kinase 2 is also present in the cytoplasmic tail. Two transcript variants encoding the same protein have been found for this gene. [provided by RefSeq].

MPZL2 Antibody (Center) Blocking Peptide - References

Kim, H., et al. Pharmacogenomics 10(2):171-179(2009) Lamesch, P., et al. Genomics 89(3):307-315(2007) Clark, H.F., et al. Genome Res. 13(10):2265-2270(2003) Guttinger, M., et al. J. Cell Biol. 141(4):1061-1071(1998)